1 **Rational Empiric Antibiotic Escalation Applied to Specific Patient Groups** 2 3 **Ranjeet Bamber** 4 Department of Population Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol. UK 5 6 **Brian Sullivan** Department of Population Health Sciences, Bristol Medical School, Faculty of Health Sciences, 7 University of Bristol, Bristol. UK 8 9 Léo Gorman Jean Golding Institute, University of Bristol, Bristol. UK 10 11 Winnie WY Lee School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol. UK 12 13 **Matthew B Avison** School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol. UK 14 15 **Andrew W Dowsey** Department of Population Health Sciences, Bristol Medical School, Faculty of Health Sciences, 16 17 University of Bristol **Philip Williams\*** 18 19 University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol. UK 20 21 Running title: Rational Empiric Antibiotic Escalation Applied to Specific Patient Groups

22 **Rational Empiric Antibiotic Escalation Applied to Specific Patient Groups** 23 Abstract 24 25 Background 26 27 Clinicians commonly escalate empiric antibiotic therapy due to poor clinical progress, without 28 microbiology guidance. When escalating, they should take account of how resistance to an initial 29 antibiotic affects the probability of resistance to subsequent options. The term Escalation 30 Antibiogram (EA) has been coined to describe this concept. One difficulty when applying the EA 31 concept to clinical practice is understanding the uncertainty in results and how this changes for 32 specific patient subgroups. 33 Methods 34 35 A Bayesian model was developed to estimate antibiotic resistance rates in Gram-negative 36 bloodstream infections based on phenotypic resistance data. It provides an expected value 37 (posterior mean) with 95% credible interval to illustrate uncertainty, based on the size of the patient 38 subgroup, and estimates probability of inferiority between two antibiotics. This model can be 39 applied to specific patient groups where resistance rates and underlying microbiology may differ 40 from the whole hospital population. 41 Results 42 43 Rates of resistance to empiric first choice and potential escalation antibiotics were calculated for the 44 whole hospitalised population based on 10,486 individual bloodstream infections, and for a range of specific patient groups, including ICU, haematology-oncology, and paediatric patients. Differences in 45 optimal escalation antibiotic options between specific patient groups were noted. 46 47 Conclusions 48 49 EA analysis informed by our Bayesian model is a useful tool to support empiric antibiotic switches, 50 providing an estimate of local resistances rates, and a comparison of antibiotic options with a 51 measure of the uncertainty in the data. We demonstrate that EAs calculated for the whole 52 population cannot be assumed to apply to specific patient groups. 53

## **Key Summary Points**

54 55

56

57

58

59 60

61 62

63

64

- Clinicians commonly escalate empiric antibiotic therapy due to poor clinical progress, without microbiology guidance.
- When escalating, they should take account of how resistance to an initial antibiotic affects the probability of resistance to subsequent options.
- We describe a Bayesian model to guide empiric antibiotic escalation, based on local resistance data, that can be applied to small patient groups to predict rates of resistance with credible intervals.
- We demonstrate that the optimal antibiotic escalation for the whole population cannot be assumed to apply to specific patient groups, such as ICU or haematology patients.

### Introduction

In many countries, initial empiric antibiotic (AB) choices for the management of bacterial infections are informed by local guidelines that in turn rely on an understanding of local phenotypic AB resistance (ABR) patterns from blood culture isolates and other sample types. This initial AB selection usually takes place within an hour of diagnosis of infection, and well before any microbiological results are available. Furthermore, microbiological culture is a relatively insensitive technique. Even in patients with sepsis, only 30–50% will have a positive blood culture (1, 2). Hence, it is also common for clinicians to empirically escalate AB therapy due to poor clinical progress in the absence of positive microbiology as a guide. While a poor clinical response may be due to a variety of factors, for example inadequate source control, it is the possibility of resistance to the first-choice treatment that usually drives escalated AB therapy. In this context, therefore, it is not the local rate of resistance to the possible second-choice AB options that should be considered, but the rate of coresistance to these agents in isolates resistant to the first AB choice. Though widely available, local phenotypic resistance data are an underused resource, and could be used to gain a better understanding of circulating co-resistance patterns and improve initial and escalated empiric AB choice.

Some prior studies have explored this approach. As part of a medical decision support system tool Zalounina *et al* (3) included prior AB treatments and local co-resistance data to guide subsequent AB choice. Wong *et al* (4) investigated 3,280 Gram-negative bacillus (GNB) blood stream infections (BSI) looking at the correlation coefficients between pairs of ABs, and the ABR profiles of subsets of isolates resistant to a specified AB. They discussed examples of how these data could be used to guide empiric AB escalation. They also suggested that local, unit based, ABR profiles and co-resistance patterns may be more useful than nationally collected data. Recently, Teitelbaum *et al* (5) took a similar approach looking at GNB BSIs. They coined the term "escalation antibiogram (EA)" to describe a profile of resistance to a set of ABs given resistance to an initial set of 12 ABs. Their local resistance patterns were stable over the period studied, including 6577 GNB BSI episodes, from 6 hospitals in their area allowing the data to be combined and averaged over time. They noted local EAs were easy to generate, however they did not have the data available to subgroup by presumed BSI source, and noted that the data may not generalise to specific patient groups.

One difficulty faced when applying the local EA concept to specific patient groups is the small numbers involved. Moreover, rates of ABR may vary over time and can vary significantly from country to country (6) and between regions within a country (7,8). Hence when attempting to produce an EA applicable to certain patient groups, taking an average over several years will not always be appropriate, nor is it possible to get extra power by combining data from other regions without diluting the desired effects of providing an EA based on local resistance data. Hence, our objective was to develop and validate a model that allows tracking of variation in local ABR and coresistance over time, and so maximises our ability to define an EA for specific patient groups. Our focus here was on ICU patients, haemato-oncology patients, patients with specific sources of BSI, and adults over 80 years. The Bayesian model scripts we developed for local use can be applied to train the model for any region.

108 Methods 109 Data collection and cleaning 110 Data were collected from 3 NHS Trusts covering 4 hospitals in the Southwest of England serving a 111 population of approximately 1.5 million people (Royal United Hospital Bath NHS Foundation Trust, 112 University Hospitals Bristol & Weston NHS Foundation Trust, and North Bristol NHS Trust) which 113 share a single laboratory information management system (Winpath Enterprise 7.23, Clinisys). 114 Positive blood cultures from all 4 hospitals where GNBs were isolated over a 6-year period, from 115 2017 to 2022, were included. 116 For each isolate, the ABR profile was determined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) disc testing or by the Biomerieux Vitek 2 automated system. Direct 117 disc sensitivities were obtained using EUCAST criteria following the Gram stain. In most cases (85%) 118 119 isolates from a purity plate were tested using the Vitek 2 system the following day giving ABR 120 profiles for a wider range of ABs. Vitek results, when available, were used in preference to the initial disc testing. Results were expressed as "Sensitive", "Intermediate", or "Resistant". Following usual 121 122 clinical practices "Intermediate" and "Resistant" isolates were grouped together as non-susceptible, which from now on we will refer to as "Resistant". Healthcare systems that have adopted EUCAST 123 124 V14 break points may elect to combine "Sensitive" and "Increase dose" as one group. When using a 125 time series of categorical data, changes to the definition of a category e.g. a change in break points 126 should be delt with by re-categorising the whole data set for affected organisms using MIC data and 127 new break points. Producing an R script to do this would be a trivial task. 128 Repeat samples from the same patient with an indistinguishable isolate (Species ID and ABR profile) 129 which occurred within 1 year were removed. Following de-duplication, we had 10,486 GNB BSIs over 130 the 6-year period. For Pseudomonas spp. and Stenotrophomonas spp. isolates, ABs that are not 131 tested due to assumed intrinsic resistance were automatically set to Resistant. 132 From 2020 onwards, the presumed source of BSI was recorded in a two-level hierarchical system, 133 with the highest level consisting of the following groups: central nervous system, cardiac, gastro-134 intestinal, urine/renal, bone/joint, skin/soft tissue, respiratory, reproductive tract, mouth/head and neck, line infection, contaminant, unknown, or other. Data were extracted every 3 months and 135 136 missing data filled in by case note review. 137 Technical details of the Bayesian model 138 A Bayesian model was developed that estimates ABR rate in GNB BSI and provides an expected value 139 140 (posterior mean) and 95% credible interval of ABR rate for a given AB at any chosen time point 141 within the 6 years of data collected. 142 Formally, we use a generalised additive model with a Bernoulli likelihood and logit link function for the binary outcome (Sensitive/Resistant) and a time varying covariate modelled by a penalised thin-143 plate regression spline. The model generates a series of "credible" curves to fit the resistance data, 144 145 each with the same probability of representing the true rate given the inherent uncertainty. To avoid overfitting, an integrated penalisation term adaptively smooths the curves given the level of 146 147 evidence. The model is implemented with the R package 'brms' (9), which adopts the Stan platform 148 for Bayesian inference with Hamiltonian Monte-Carlo sampling (10). Four chains are run for 4,000 149 iterations, with the first 50% discarded as warm-up, leading to 8,000 plausible curves fitting the data.

151

152

153

154155

156

157

158

159

160

161

162

163164

165166

167

168169

170

171

172

173

174

Statistics such as mean and credible intervals can be directly computed from samples of the curves at the required times. Resistance rates between two groups or time points are compared by subtracting one set of curves from another, allowing us to calculate the posterior probability of an increase (PPI) or decrease (PPD) in resistance over time or the posterior probability of inferiority (PPInf), or superiority (PPSup) between two AB options. In keeping with the philosophy of a Bayesian approach we do not attempt to define what probability of difference or superiority is significant, but to simply provide that probability of a difference with the 95% credible interval. **Results & Discussion** Changes in ABR over time Over a 6-year period between 2017 to 2022, ABR rates were calculated for deduplicated GNB BSI in patients across our local hospitals (n=10,486). An example of this output, piperacillin/tazobactam resistance in haemato-oncology patients is reported (Fig. 1). The resistance rate increased for meropenem (1.5% to 2.2%, PPI = 88.7%), but reduced slightly (See supplementary material) in all other ABs studied (piperacillin/tazobactam (Tazocin), gentamicin, amikacin, cefotaxime, ceftazidime, ciprofloxacin, trimethoprim/sulfamethoxazole (Cotrimoxazole) and amoxicillin/clavulanate (Coamoxiclav). The reductions ranged from 2.3% in Ceftazidime (Fig. 2a) (PPD = 94.3%), to 6.9% in trimethoprim/sulfamethoxazole resistance rate (Fig. 2b) (PPD = 98.5%). This larger reduction in resistance may be related to the removal of trimethoprim as first-line treatment for lower urinary tract infection in local community guidelines from April 2017, which resulted in a reduction in trimethoprim resistance in E. coli from community urine samples (11).

176

177178

179

180

181

182

183184

185

186

187

188

189

190 191

192

193

194

195

196

197

198

199 200

201

202

203

204

205

206

207

208

209

210

211

212

213

Informing empiric AB choice in specific patient groups When examining resistance to specific ABs in specific patient populations, the 95% CI tends to widen due to the reduced sample size. For example, piperacillin/tazobactam resistance in GNB BSIs in ICU patients has a much wider 95% CI compared to the whole hospital data, as the former is based on 695 positive blood cultures compared to 10,486 for the latter (Fig. 3a, 3b). Over time, piperacillin/tazobactam resistance rates have increased for ICU patients and haemato-oncology patients (fig. 3b, 3c), while reducing over the whole hospital population (fig. 3a). Clearly, therefore, using the mean resistance rate for piperacillin/tazobactam over the 6-year period to inform empiric AB choice would underestimate the current resistance rate in the ICU and haemato-oncology populations, while using only the last year or few months data would be excessively influenced by random month-to-month variation in small patient groups. Our model overcomes this issue as the time series data allows us to estimate current ABR rates, and the uncertainty, while the model borrows information from the earlier data. Following this example, the posterior means between piperacillin/tazobactam resistance rates in GNB BSI isolates from the ICU population and the whole hospital population are different (27.4% vs 13.4%, respectively), and the 95% CIs do not overlap, suggesting this difference is reliable. The probability that ICU patients have higher resistance rates can be computed simply as the proportion of curves that are higher in models of the ICU population than the whole hospital population at this timepoint, in this case, PPI = 99.9%. In contrast, the difference between the posterior mean piperacillin/tazobactam resistance rates for BSI GNBs from ICU and haemato-oncology patients is small (27.4% vs 30.7%) and there is a considerable overlap in the 95% CIs. This is reflected in the calculated posterior probability of 67.5% that piperacillin/tazobactam resistance rate is lower in the ICU population compared with the haemato-oncology population (e.g., PPD = 67.5%) or conversely there is a 32.5% probability that the resistance rate is greater in ICU patients than in haemato-oncology patients (e.g., PPI = 32.5%). The situation for ceftazidime is similar, with a higher (and increasing) rate of resistance in both ICU and haemato-oncology patients compared to the whole hospital population. Both ICU and haematooncology patients have a higher proportion of potentially AmpC hyper-producing "SPACE" (Serratia, Pseudomonas, Acinetobacter, Citrobacter & Enterobacter) isolates compared to the whole population (ICU 38% vs 25%, PPD = 99.3%) and haemato-oncology (30% vs 25%, PPD = 87.0%) which explains a proportion of the higher resistance rates. The increase in ceftazidime resistance over time is likely greater in haemato-oncology patients (15.2% to 24.5%, PPI = 89.4%) than ICU (17.6% TO 20%, PPI = 66.3%), and is due to both increased resistance in non-E. coli isolates include in SPACE organisms, (Figure 4) and in an increase in the proportion of non-E. coli isolates (E. coli reduced from 44% to 35%, PPD = 82%, in haematooncology, while in ICU the proportion of *E. coli* remained at 27%)

Calculating an escalation antibiogram (EA) for specific patient groups

- To calculate an EA, our Bayesian model is applied for any given second-choice AB to all isolates
- 216 resistant to the first-choice AB. Table 1 reports these data for the whole hospital population express
- as a most likely rate of resistance with 95% credible intervals. In this population if moving away from
- 218 piperacillin/tazobactam we would predict 27% (95% CI 18 to 24) if moving to gentamicin and 31%
- 219 (95% CI 21 to 40) if switching to ciprofloxacin.
- We can also calculate the probability of inferiority (PPInf) between pairs of alternative antibiotics.
- This is shown in figure 5 using data for ICU patients assuming piperacillin/tazobactam resistance.
- When making a clinical decision on antibiotic selection, the probability of inferiority is only useful
- when both alternatives have a suitably low rate of resistance.
- 224 It is worth noting that GNB BSI resistance rates to meropenem are low in this region (~2%), where
- meropenem is invariably superior as an empiric choice. Our analysis has therefore focused on other
- 226 ABs as meropenem-sparing alternatives. Similarly within our region, resistance rates to newer
- 227 antibiotics such as Cetazidime-Avibactam or Meropenem-Vaborbactam are currently too low to
- allow inclusion in our analysis.

214

229

230

253

### **Escalation Antibiogram Example 1**

- In severe Gram-negative infections, two of the most commonly used  $\beta$ -lactams are
- 232 piperacillin/tazobactam (first-line AB for neutropenic sepsis and widely used in ICU) and ceftazidime
- 233 (a useful alternative to piperacillin/tazobactam especially in non-severe penicillin allergy). In our
- region, piperacillin/tazobactam and ceftazidime resistance rates among GNB BSIs are similar: 13.4%
- 235 (95% CI 10.8 to 16.1) and 10.6% (95% CI 8.9 to 12.7) respectively. The merits of the addition of an
- aminoglycoside to a  $\beta$ -lactam has been much debated (12,13) but will inevitably depend on local
- resistance and co-resistance rates. We will look at the effect of resistance to piperacillin/tazobactam
- and ceftazidime on the probability of resistance to gentamicin (our mostly widely used
- aminoglycoside) and amikacin (which is rarely used locally) in two specific patient groups, ICU
- patients and haemato-oncology and compare these results with those generated from the whole
- 241 hospital population.
- 242 When comparing a wide group of second line options when adding to, or switching from
- 243 piperacillin/tazobactam or ceftazidime (Tables 2 and 3), ABs are ordered in preference for whole
- 244 hospital populations, showing the percent resistant with 95% CI, and with the PPInf to that in the
- column on its left in the table. Values under 50% indicate the AB is superior to that on its left.
- 246 Resistance rates to both aminoglycosides are much higher in isolates resistant to either ceftazidime
- or piperacillin/tazobactam, with resistance rates vary from 14% to 39% depending on the patient
- group and antibiotic combinations compared to 3% to 13% aminoglycoside resistance in all isolates.
- 249 Within the whole hospital population, amikacin remains the best option for patients switching from
- either ceftazidime or piperacillin/tazobactam, with a 97% & 95% probability of superiority compared
- 251 to gentamicin, although there is a greater relative increase in amikacin resistance compared to
- 252 gentamicin (see Tables 2 and 3).
- 254 Within the ceftazidime and piperacillin/tazobactam resistant isolates, both the ICU and haemato-
- 255 oncology populations differ from the whole hospital population with lower rates of aminoglycoside
- resistance in ICU, and higher rates of resistance in haemato-oncology patients (Fig 6). Within ICU

patients amikacin is likely to be superior, PPSup = 69.8% if switching from piperacillin/tazobactam and PPSup = 71% if switching from ceftazidime. For the haemato-oncology patients there is little difference between amikacin and gentamicin, (PPSup = 52%) although there is a noticeably higher rate of resistance for both when switching from ceftazidime compared to piperacillin/tazobactam (also see plots in supplementary material).

A difference between whole population and ICU or haemato-oncology populations are seen in a range of other antibiotics. Within the ICU patients, ciprofloxacin, trimethoprim/sulphamethoxazole and gentamicin have a similar probability of sensitivity, which is noticeably lower than in the whole hospital population. While within the haemato-oncology cohort, resistance rates to amikacin and gentamicin are higher than in the general population, and resistance rates to ciprofloxacin and trimethoprim/sulphamethoxazole are similar, despite both being used in some prophylaxis regimes. The resistance rates for all options are high (30-40%), so in a neutropenic patient, meropenem would be a more suitable alternative.

It is clear therefore, that sub-population analysis will be required by those intending to apply the EA in clinical practice.

### **Escalation Antibiogram Example 2**

- Having noted how changes in resistance over time differ between species, for example cefotaxime resistance in *E. coli* and non-*E. coli* (See supplementary material), we confirmed that this effect was also present in piperacillin/tazobactam resistant isolates. (Fig 7). We then looked at two clinical groups with a high proportion of *E. coli* infections (patients over 80 years old and patients with a urinary source of infection) to determine if they differed from the whole hospital population (Tables 4 and 5).
- Overall, the proportion of BSI caused by *E. coli* has very likely decreased from 59.1% (95%CI 54.9 to
- 282 63.8) at the start of 2017 to 51.4% (95%CI 47.1 to 55.5, PPD = 99.6%) at the end of 2022. Within
- 283 patients over 80 years old, and patients with a BSI of urine or renal tract source we have seen a
- similar decrease in the proportion of *E. coli* BSI, to a current rate of 59.7% (95%CI 54.3 to 64.4) from
- 285 68% (95%CI 63.5 to 72.9, PPD = 99.3%) and 57.8 (95%CI 48.5 to 64.4) from 65.6% (95%CI 58.2 to
- 286 71.9, PPD = 94.5%) respectively.
- 287 When switching from piperacillin/tazobactam (Table 4) it appears that amikacin is the best option,
- but in circumstances where an aminoglycoside could not be used (e.g., poor renal function),
- cefotaxime is comparable to ciprofloxacin and superior to co-trimoxazole for urinary source
- 290 infections.

257258

259

260

261

262

263264

265

266

267268

269

270

271

272

273

- 291 We would not usually think of empirically changing from piperacillin/tazobactam to cefotaxime, as
- the former is usually considered to be broader spectrum, and it is often assumed that resistance to
- 293 piperacillin/tazobactam would also confer resistance to 3<sup>rd</sup> generation cephalosporins. While AmpC
- 294 enzymes can confer resistance to both classes, when ESBL-producing isolates are reported as
- 295 piperacillin/tazobactam resistant, this can be due to a range of β-lactamases which are not routinely
- 296 identified in clinical isolates. β-Lactamases including OXA-1, inhibitor resistant TEM, or the high
- levels of TEM-1 can result in piperacillin/tazobactam resistance, independently of 3<sup>rd</sup> generation
- 298 cephalosporins resistance (14).

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339 340

(HDR CF0129).

Assuming ceftazidime resistance (Table 5) showed that amikacin is clearly superior in the urinary source group, whereas for over 80s, amikacin or gentamicin are broadly comparable. Due to the high resistance rates of co-trimoxazole and ciprofloxacin, meropenem would be suitable if an aminoglycoside could not be used. **Conclusions** Failure of empiric AB therapy is a regularly encountered clinical problem for infection speicialist. EA analysis informed by our Bayesian model is a useful tool to support clinician decision making in escalation of empiric AB therapy for the deteriorating patient when microbiology results are not available. The model produces a mean resistance rate, with 95% credible intervals for any AB option, and allows the calculation of a posterior probability that one AB choice is superior to another based on local ABR patterns. The clinical application of this model requires the use of data appropriate to the patient group being treated and an understanding of the uncertainty in the data – this uncertainty will increase when applying the concept to relatively small patient groups. We conclude that within our region, the application of whole hospital data to groups with different underlying presentations and AB exposures such as haemato-oncology patients or paediatric patients is not appropriate. To overcome this shortcoming of simple EA analysis, we have focused on patient groups that can be determined before blood culture results are known, based on age, presumed source of infection, ICU patients or haemato-oncology patients. We have avoided the use of species-specific antibiograms, preferring to use those based on the mix of species found in the patient group under consideration. We note the differences in species proportions between groups appears to explain a significant amount of the resistance difference. We anticipate that the results of our EA analysis in a given institution would be utilised by infection specialists, rather than general clinicians, to avoid potentially inappropriate AB choices, such as the use of aminoglycosides as a single agent where this contraindicated, and to ensure that alternative reasons for poor response to empiric AB therapy (e.g. lack of source control) are considered. Our model can be easily introduced in any institution using the freely available software package, R. It requires only appropriately cleaned and de-duplicated ABR data which, in many cases, is already generated regularly to inform antimicrobial guideline development. This process of gathering data can also be automated, as in our centre, to further reduce the associated workload, and the model can be run as often as indicated by local demands. We suggest that this model is suitable for widespread adoption across institutions where infection specialists are making antimicrobial escalation decisions in the absence of helpful microbiological results. **Ethics** This was a retrospective study using anonymised data already collected as part of routine clinical care. This project was approved by Public Health England's Research Ethics and Governance Group (REGG). **Funding** P.W., M. B. A. & A.W.D. were supported by Medical Research Council grant MR/T005408/1 R.B., & B.S. were supported by Health Data Research UK via the Better Care Partnership Southwest

- 341 W.W.Y.L. received a scholarship from the Medical Research Foundation National PhD Training
- Program in Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO).

### Transparency declarations

345 All authors confirm that they have no conflicts of interest to declare.

### **Author Contributions**

- 348 Conceived the Study and Obtained Funding: P.W., A.W.D., M.B.A.
- Cleaning and Analysis of Data: R.B., B.S., L.G., W.W.Y.L., A.W.D., P.W.
- 350 Initial Drafting of Manuscript: P.W., M.B.A.
- 351 Corrected and Approved Manuscript: All authors
- 352 References

343

344


346

347


- 1. Scheer, C. S., Fuchs, C., Gründling, M., Vollmer, M., Bast, J., Bohnert, J. A., ... & Kuhn, S. O. (2019).
- 354 Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a
- 355 prospective clinical cohort study. Clinical Microbiology and Infection, 25(3), 326-331.
- 357 2. Murray, P. R., & Masur, H. (2012). Current approaches to the diagnosis of bacterial and fungal
- 358 bloodstream infections for the ICU. Critical care medicine, 40(12), 3277.
- 359 3. Zalounina, A., Paul, M., Leibovici, L., & Andreassen, S. (2007). A stochastic model of susceptibility
- 360 to antibiotic therapy—the effects of cross-resistance and treatment history. Artificial Intelligence in
- 361 Medicine, 40(1), 57-63.
- 4. Wong, P. H., von Krosigk, M., Roscoe, D. L., Lau, T. T., Yousefi, M., & Bowie, W. R. (2014).
- 363 Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a
- longitudinal epidemiological study from 2002–2011. BMC infectious diseases, 14(1), 1-10.
- 365 5. Teitelbaum, D., Elligsen, M., Katz, K., Lam, P. W., Lo, J., MacFadden, D., ... & Daneman, N. (2022).
- 366 Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in
- the Nonresponding Patient. Clinical Infectious Diseases, 75(10), 1763-1771.
- 368 6. Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... & Tasak, N. (2022).
- 369 Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet,
- 370 399(10325), 629-655.
- 371 7. Quarterly laboratory surveillance of acquired carbapenemase-producing Gram-negative bacteria
- in England: October 2020 to September 2022
- 373 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file
- 374 /1135930/hpr0223-CPGNB-Q32022-v2.pdf
- 375 8. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) Report 2021
- 376 to 2022
- 377 <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment</a> data/file
- 378 /1118310/ESPAUR-report-2021-to-2022.pdf

9.. Bürkner P (2017). "brms: An R Package for Bayesian Multilevel Models Using Stan." Journal of Statistical Software, 80(1), 1–28. doi:10.18637/jss.v080.i01. 10. Stan platform for Bayesian inference with Hamiltonian Monte-Carlo sampling. Stan Development Team. 2022. Stan Modeling Language Users Guide and Reference Manual, VERSION. https://mc-stan.org 11. Hammond, A., Stuijfzand, B., Avison, M. B., & Hay, A. D. (2020). Antimicrobial resistance associations with national primary care antibiotic stewardship policy: Primary care-based, multilevel analytic study. PloS one, 15(5), e0232903. 12. Paul, M., Soares-Weiser, K., & Leibovici, L. (2003). β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Bmj, 326(7399), 1111. 13. Tang, Y., Wu, X., Cheng, Q. et al. Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections. Infection 48, 109–116 (2020). https://doi.org/10.1007/s15010-019-01370-x 14): Davies TJ, Stoesser N, Sheppard AE, Abuoun M, Fowler P, Swann J, Quan TP, Griffiths D, Vaughan A, Morgan M, Phan HTT, Jeffery KJ, Andersson M, Ellington MJ, Ekelund O, Woodford N, Mathers AJ, Bonomo RA, Crook DW, Peto TEA, Anjum MF, Walker AS. Reconciling the Potentially Irreconcilable? Genotypic and Phenotypic Amoxicillin-Clavulanate Resistance in Escherichia coli. Antimicrob Agents Chemother. 2020 May 21;64(6):e02026-19. doi: 10.1128/AAC.02026-19. PMID: 32205351; PMCID: PMC726950 


### 415 Figures




**Figure 1.** Piperacillin/tazobactam resistance in haemato-oncology patients. (Top) A stacked barplot representing the number of samples in the data. (Middle) A 'spaghetti plot' of a random selection of splines fitted to the data that make up the model, and (Bottom) a 'ribbon' plot showing the inferred posterior mean (black line) with the 66% and 95% credible interval (dark and light blue shaded areas) with the quarterly rates shown as dots.




**Figure 2.** All deduplicated GNB BSI isolates (n=10486) (a) Percent Resistance to Ceftazidime reduces from 12.9% (95% CI 10.9 to 15.3) in 2017 to 10.6% (95% CI 8.8 to 12.9) in 2022. (b) % Resistance to trimethoprim/sulfamethoxazole reduces from 32.9% (95% CI 28.3 to 36.4) in 2017 to 26.0% (95% CI 22.7 to 29.4) in 2022




**Figure 3.** Piperacillin/tazobactam resistance for all patients (Top) compared to ICU patients (Middle) and haemato-oncology patients (bottom)




**Figure 4.** Percent resistance to ceftazidime in all isolates (left column) and non-E coli isolates (right column) located in either (Top Row) ICU (Bottom row) or Haematology/Oncology.



**Figure 5.** For ICU patients with assumed resistance to piperacillin/tazobactam. The estimated resistance rate to 6 antibiotic options with the 66% and 95% credible interval is shown on the left. The centre and right plots each show a head to head comparison between one antibiotic (Amikacin or Ciprofloxacin) and the other five antibiotics. This gives the estimated difference in probability of resistance, for example, there is 41% probability of higher resistance in amikacin compared to ciprofloxacin (right), only marginally favouring amikacin, while there is an 81% probability of higher resistance in co-trimoxazole compared to ciprofloxacin (right) favouring the use of ciprofloxacin.



**Figure 6.** Percent Resistance to gentamicin assuming piperacillin/tazobactam resistance in (Top) all isolates 27.0% (95% CI 18.5 to 34.5), (Middle) ICU 19.2% (95% CI 7.1 to 37.0), (Bottom) haemato-oncology 33.5% (95% CI 14.6 to 57.5)



**Figure 7.** (Top) Cefotaxime resistance in all isolates assuming piperacillin/tazobactam resistance was stable over time 43.7% (95% CI 33 to 53) PPD = 46.1%. (Bottom) Cefotaxime resistance in E. coli assuming piperacillin/tazobactam resistance reduced from 29.2% (95%CI 20.4 to 38.6) to 18.3% (95%CI 11 to 28) PPD = 95.5%

### 473 Tables

Initial Choice Antibiotic

# Second Choice Antibiotic Meropenem

#### **Posterior Mean** Upper 97.5% CI Lower 2.5% CI Meropenem NA NA NA 0.07 0.12 0.18 Pip.Taz Ceftazidime 0.07 0.13 0.21 Cefotaxime 0.12 0.18 0.08 Cefuroxime 0.07 0.11 0.05 Gentamicin 0.28 0.07 0.15 Amikacin 0.24 0.46 0.11 Coamoxiclav 0.05 0.03 0.07 Ciprofloxacin 0.03 0.07 0.01 Cotrimoxazole 0.04 0.07 0.02

## Second Choice Antibiotic Pipercillin/Tazobactam

Pipercillin/Tazobactam						
Posterior Mean	Upper 97.5% CI	Lower 2.5% Cl				
0.67	0.83	0.47				
NA	NA	NA				
0.57	0.68	0.43				
0.34	0.44	0.24				
0.29	0.36	0.22				
0.46	0.58	0.33				
0.65	0.89	0.44				
0.26	0.32	0.21				
0.34	0.45	0.23				
0.18	0.23	0.13				

# Second Choice Antibiotic Ceftazidime

		Posterior Mean	Upper 97.5% CI	Lower 2.5% CI
	Meropenem	0.62	0.78	0.43
C	Pip.Taz	0.47	0.56	0.38
ioti	Ceftazidime	NA	NA	NA
Initial Choice Antibiotic	Cefotaxime	0.51	0.59	0.44
e A	Cefuroxime	0.36	0.42	0.31
oic	Gentamicin	0.45	0.59	0.35
J C	Amikacin	0.67	0.88	0.47
nitic	Coamoxiclav	0.2	0.24	0.17
"	Ciprofloxacin	0.41	0.5	0.33
	Cotrimoxazole	0.18	0.22	0.14

# Second Choice Antibiotic Cefotaxime

Posterior Mean	Upper 97.5% CI	Lower 2.5% Cl
0.89	0.99	0.62
0.44	0.53	0.33
0.78	0.86	0.67
NA	NA	NA
0.57	0.62	0.52
0.45	0.59	0.35
0.74	0.9	0.58
0.32	0.37	0.27
0.42	0.52	0.33
0.42	0.49	0.34
<u> </u>		·

# Second Choice Antibiotic Cefuroxime

	Posterior Mean	Upper 97.5% CI	Lower 2.5% CI
Meropenem	0.95	1	0.82
Pip.Taz	0.63	0.71	0.53
Ceftazidime	0.97	0.99	0.93
Cefotaxime	0.99	1	0.98
Cefuroxime	NA	NA	NA
Gentamicin	0.58	0.71	0.47
Amikacin	0.81	0.94	0.67
Coamoxiclav	0.53	0.59	0.47
Ciprofloxacin	0.63	0.74	0.54
Cotrimoxazole	0.5	0.57	0.43

# Second Choice Antibiotic Gentamicin

Posterior Mean	Upper 97.5% CI	Lower 2.5% CI
0.45	0.64	0.28
0.27	0.34	0.18
0.33	0.41	0.25
0.21	0.27	0.16
0.15	0.2	0.12
NA	NA	NA
0.61	0.78	0.41
0.13	0.17	0.1
0.35	0.43	0.27
0.17	0.22	0.12

Initial Choice Antibiotic

# Second Choice Antibiotic Amikacin

474

475

476

477

478

479

480

481

482

483

484

Meropenem

Pip.Taz

Ceftazidime

Cefotaxime

Cefuroxime

Gentamicin

Amikacin

Coamoxiclav

Ciprofloxacin

Cotrimoxazole

Initial Choice Antibiotic

### **Posterior Mean** Upper 97.5% CI Lower 2.5% CI 0.41 0.23 0.62 0.18 0.25 0.11 0.2 0.3 0.12 0.16 0.23 0.1 0.1 0.15 0.06 0.23 0.37 0.11 NA NA NA

0.09

0.25

0.09

0.03

0.08

0.02

# Second Choice Antibiotic Coamoxiclav

Coamoxiciav					
Posterior Mean	Upper 97.5% CI	Lower 2.5% Cl			
0.99	1	0.94			
0.91	0.96	0.84			
0.87	0.92	0.8			
0.9	0.94	0.83			
0.85	0.89	0.8			
0.82	0.89	0.73			
0.85	0.94	0.71			
NA	NA	NA			
0.72	0.8	0.64			
0.78	0.82	0.73			

# Second Choice Antibiotic Ciprofloxacin

		Posterior Mean	Upper 97.5% CI	Lower 2.5% CI
	Meropenem	0.23	0.45	0.09
C	Pip.Taz	0.31	0.4	0.21
Initial Choice Antibiotic	Ceftazidime	0.45	0.54	0.35
ntib	Cefotaxime	0.29	0.38	0.22
e A	Cefuroxime	0.24	0.31	0.19
hoic	Gentamicin	0.55	0.66	0.43
J C	Amikacin	0.66	0.86	0.41
nitic	Coamoxiclav	0.17	0.21	0.13
"	Ciprofloxacin	NA	NA	NA
	Cotrimoxazole	0.24	0.3	0.19

0.06

0.16

0.05

# Second Choice Antibiotic Cotrimoxazole

Posterior Mean	Upper 97.5% CI	Lower 2.5% Cl
0.58	0.75	0.39
0.37	0.45	0.27
0.43	0.53	0.33
0.67	0.75	0.58
0.46	0.52	0.39
0.58	0.71	0.45
0.45	0.64	0.24
0.44	0.48	0.39
0.58	0.67	0.49
NA	NA	NA

**Table 1.** Posterior mean resistance estimates with 95% credible intervals for the whole hospital population. Tables for haemato-oncology, paediatrics, GI or urinary source infections are in the supplementary material.

Pip/Taz Resistant	Amikacin	Gentamicin	Ciprofloxacin	Co-trimoxazole	Cefotaxime	Ceftazidime
All (% R with CI)	18% (11 to 25)	27% (18 to 34)	31% (21 to 40)	37% (28 to 45	44% (33 to 53)	47% (37 to 55)
All (% inferior)		95.0%	73.7%	81.9%	82.8%	72.5%
ICU (% R with CI)	14% (4 to 33)	19% (7 to 37)	17% (6 to 33)	23% (10 to 40)	65% (41 to 83)	63% (46 to 84)
ICU (% inferior)		69.8%	39.4%	74.6%	99.9%	45.5%
Haem (% R with CI)	31% (9 to 55)	32% (7 to 57)	31% (8 to 62)	42% (16 to 74)	58% (32 to 81)	62% (34 to 84)
Haem (% inferior)		52.8%	49.5%	71.5%	81.7%	41.2%

Table 2. Escalation antibiogram for piperacillin/tazobactam (pip/taz) resistant isolates showing resistance rate and the posterior probability of inferiority (PPInf) to the antibiotic choice to the choice to the immediate left (e.g., Gentamicin v. Amikacin, Ciprofloxacin v. Gentamicin, etc.) across the whole hospital and in subgroups from ICU and Haematology/Oncology. Numbers in brackets indicate upper and lower bounds for the 95% credible interval.

Ceftazidime	Amikacin	Gentamicin	Co-trimoxazole	Ciprofloxacin	Pip/Taz	Cefotaxime
Resistant						
All (% R or I)	21% (12 to 30)	33% (24 to 41)	43% (33 to 52)	45% (35 to 54)	57% (43 to 687)	78% (67 to 86)
All (% inferior)		97.2%	94.4%	62.4%	92.4%	99.7%
ICU (% R or I)	17% (4 to 42)	24% (7 to 44)	27% (10 to 49%)	28% (11 to 52)	86% (66 to 98)	88% (70 to 98
ICU (% inferior)		71.0%	58.3%	53.5%	99.9%	59.7%
Haem (% R or I)	38% (18 to 62)	39% (19 to 64)	39% (16 to 64)	35% (13 to 61)	77% (54 to 92)	88% (69 to 98)
Haem (% inferior)		52.3%	50.1%	40.1%	99.2%	84.6%

Table 3. Escalation antibiogram for Ceftazidime resistant isolates showing resistance rate and the PPInf to the antibiotic choice to the choice to the immediate left (e.g., Gentamicin v. Amikacin, Ciprofloxacin v. Gentamicin, etc.) across the whole hospital and in subgroups from ICU and Haematology/Oncology. Numbers in brackets indicate upper and lower bounds for the 95% credible interval.

Pip/Taz Resistant	Amikacin	Gentamicin	Ciprofloxacin	Co-trimoxazole	Cefotaxime	Ceftazidime
All (% R or I)	18% (11 to 25)	27% (18 to 34)	31% (21 to 40)	37% (28 to 45	44% (33 to 53)	47% (378 to 55)
All (% inferior)		95.0%	73.7%	81.9%	82.8%	72.5%
Over 80 (% R or I)	16% (5 to 29)	19% (7 to 34)	39% (22 to 54)	39% (25 to 55)	37% (20 to 53)	43% (28 to 56)
Over 80 (% inferior)		60.0%	94.6%	48.2%	43.6%	67.3%
U/R Source (% R or I)	13% (3 to 27)	29% (13 to 46)	33% (16 to 53)	39% (22 to 59)	29% (15 to 47)	36% (19 to 59)
U/R Src (% inferior)		93.2%	63.5%	68.3%	20.9%	68.4%

Table 4. Escalation antibiogram for piperacillin/tazobactam resistant isolates showing resistance rate and the posterior probability of inferiority (PPInf) to the antibiotic choice to the the choice to the immediate left (e.g., Gentamicin v. Amikacin, Ciprofloxacin v. Gentamicin, etc.). Data for whole hospital, and subgroups of patients over 80 years, and infections with urine/renal source. Numbers in brackets indicate upper and lower bounds for the 95% credible interval.

Ceftazidime Resistant	Amikacin	Gentamicin	Co-trimoxazole	Ciprofloxacin	Pip/Taz	Cefotaxime
All (% R or I)	21% (12 to 30)	33% (24 to 41)	43% (33 to 52)	45%(35 to 54)	57% (43 to 687)	78% (67 to 86)
All (% inferior)		97.2%	94.4%	62.4%	92.4%	99.7%
Over 80 (% R or I)	21% (9 to 35)	25% (11 to 40)	44% (27 to 60)	44% (24 to 63)	49% (33 to 66)	77% (62 to 88)
Over 80 (% inferior)		68%	94.3%	52.7%	60.9%	99.3%
U/R Source R or I)	13% (2 to 33)	34% (15 to 54)	48% (24 to 72)	57% (35 to 76)	49% (29 to 72)	80% (55 to 96)
U/R Src (% inferior)		93.7%	80.8%	72.2%	28.3%	96.6%

Table 5. Escalation antibiogram for ceftazidime resistant isolates showing resistance rate and the posterior probability of inferiority (PPInf) to the antibiotic choice to the the choice to the immediate left (e.g., Gentamicin v. Amikacin, Ciprofloxacin v. Gentamicin, etc.). Data for whole hospital, and subgroups of patients over 80 years, and infections with urine/renal source. Numbers in brackets indicate upper and lower bounds for the 95% credible interval.